Posts

Padcev-Keytruda Combination Shows Strong Positive Data in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

on
The Phase 3 KEYNOTE-B15/EV-304 trial demonstrated that KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin) reduced the risk of event-free survival (EFS) events by 47% and the risk of death by 35% compared to neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC) when given before and after surgery. 1 2 Statistically significant improvements in overall survival and pathological complete response were observed, with over half of patients showing no detectable disease at surgery. 2 This builds on prior Phase 3 trials like KEYNOTE-905 and KEYNOTE-A39, showing OS benefits across bladder cancer stages, potentially establishing a new standard of care. 1 2 Announced by Merck, Pfizer, and Astellas; results to be discussed with health authorities for regulatory filings. 1 2 3 Sources: 1. https://www.merck.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-reduced-risk-of-event-free-survival-events-by-47-and-risk-of-deat...

FDA’s One Trial Policy: Not a Revolution but a Potentially Risky Evolution

on

Uncertainty Looms Over Pharma's Legal Strategy as States Challenge New Vaccine Schedule

on

Boehringer Ingelheim's Hernexeos Receives Speedy FDA Approval for Lung Cancer Under CNPV Program

on

AI Tips and Prompts to Elevate Your 2026 Job Search

on

DeepHealth Achieves CE Mark for TechLive and Enables AWS Marketplace Deployment

on

Senate Hearing Criticizes FDA's Rare Disease Drug Review Process

on

Government of Canada and Partners Invest Over $41 Million in Cancer Prevention Research

on

Dexcom Appoints Google Executive Rick Osterloh to Board of Directors

on

DOJ Position on Hikma v. Amarin Skinny Label Case Before Supreme Court

on

Novartis Expands Radioligand Therapy Manufacturing with New German Facility

on

Gilead and Merck Advance Daily HIV Treatment Pills with Positive Late-Stage Data at CROI 2026

on

Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front

on